Ness Bermingham. Korro Bio

Ness Berming­ham looks to lead the wave of RNA edit­ing at new At­las up­start Ko­r­ro Bio

By the time Ness Berming­ham left In­tel­lia in late 2017, the gene-edit­ing biotech had se­cured its foot­ing as one of the pi­o­neers in the CRISPR/Cas9 space with a high­ly an­tic­i­pat­ed first-in-hu­man tri­al in the works. Re­turn­ing to his VC post at At­las Ven­ture, he sig­naled that he was look­ing to do it all over again with the next big start­up idea.

And now he’s ready to talk about that ven­ture, which rep­re­sents the lat­est evo­lu­tion of his long­stand­ing in­ter­est in tin­ker­ing with the genome — RNA edit­ing.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.